These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 20054436

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
    Sclar DA, Evans MA, Robison LM, Skaer TL.
    Clin Drug Investig; 2012 May 01; 32(5):353-60. PubMed ID: 22480280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF, Miravitlles M.
    Respir Res; 2017 May 30; 18(1):105. PubMed ID: 28558837
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
    Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM.
    Int J Chron Obstruct Pulmon Dis; 2017 May 30; 12():1295-1308. PubMed ID: 28496314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
    Piitulainen E, Mostafavi B, Tanash HA.
    Int J Chron Obstruct Pulmon Dis; 2017 May 30; 12():495-500. PubMed ID: 28203073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
    Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C.
    Int J Chron Obstruct Pulmon Dis; 2020 May 30; 15():3193-3199. PubMed ID: 33299307
    [Abstract] [Full Text] [Related]

  • 14. Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.
    Hiller AM, Piitulainen E, Jehpsson L, Tanash H.
    Int J Chron Obstruct Pulmon Dis; 2019 May 30; 14():1075-1083. PubMed ID: 31213789
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
    Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J.
    Am J Respir Crit Care Med; 1999 Nov 30; 160(5 Pt 1):1468-72. PubMed ID: 10556107
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
    Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R, Fähndrich S.
    Respir Med; 2017 Sep 30; 130():1-8. PubMed ID: 29206626
    [Abstract] [Full Text] [Related]

  • 19. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
    Am J Respir Crit Care Med; 1998 Jul 30; 158(1):49-59. PubMed ID: 9655706
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.